CI Global Health Sciences Corporate Class

Class F3 USD

FUND OVERVIEW

This fund invests primarily in equity and equity-related securities of companies around the world that specialize in the health care or medical industry.

FUND DETAILS

Inception date	May 2017
Total net assets ($CAD) As at 2019-06-30	$207.6 million
NAVPS As at 2019-08-07	$7.1646
MER (%) As at 2018-09-30	1.13
Management fee (%)	0.850
Asset class	Industry-Specific
Currency	USD
Minimum investment	$1,000,000 initial / $25 additional
Distribution frequency	Quarterly
Last distribution	$0.1435

Risk rating[3]

Low	Low to medium	Medium	Medium to high	High

FUND CODES

F	324
F1	81324
F2	82324
F3	83324
F4	84324

DISTRIBUTION HISTORY[4]

Payable date	Total	Payable date	Total
2019-06-21	0.0913	2018-03-23	0.1589
2019-03-22	0.1435		
2018-12-14	0.0224		
2018-09-14	0.0227		
2018-06-22	0.0223		

PERFORMANCE[1]

As at 2019-06-30

Growth of $10,000 (since inception date)



Calendar year performance



Average annual compound returns

YTD	1 Mo	3 Mo	6 Mo	1 Y	3 Y	5 Y	10 Y	Inception*
8.7%	5.0%	-3.8%	8.7%	-4.5%	-%	-%	-%	4.0%

*Since inception date

PORTFOLIO ALLOCATIONS[2]

As at 2019-06-30

Asset allocation	(%)
US Equity	58.79%
International Equity	36.49%
Cash and Equivalents	3.64%
Canadian Equity	1.12%
Other	-0.04%

Geographic allocation	(%)
United States	61.32%
Japan	11.74%
Germany	7.62%
United Kingdom	5.43%
Switzerland	4.44%
France	2.72%
Canada	2.14%
Other	2.11%
Singapore	1.32%
Netherlands	1.16%

Sector allocation	(%)
Healthcare	84.27%
Consumer Services	6.85%
Cash and Cash Equivalent	3.64%
Financial Services	3.45%
Real Estate	1.83%
Other	-0.04%

Note: This page is not complete without disclaimers on the next page.

CI Global Health Sciences Corporate Class

Class F3 USD

TOP HOLDINGS

As at 2019-06-30

	Sector	(%)
1. Alexion Pharmaceuticals Inc	Drugs	5.37%
2. Intercept Pharmaceuticals Inc	Drugs	5.21%
3. SeaSpine Holdings Corp	Diversified Healthcare	5.08%
4. Astellas Pharma Inc	Drugs	4.76%
5. Roche Holding AG - Participation	Diversified Healthcare	4.44%
6. Biogen Idec Inc	Drugs	4.43%
7. Takeda Pharmaceutical Co Ltd	Drugs	4.27%
8. GlaxoSmithKline PLC	Drugs	3.79%
9. Bristol-Myers Squibb Co	Drugs	3.72%
10. Compugroup Medical AG	Healthcare Services	3.57%
11. Trupanion Inc	Insurance	3.45%
12. CVS Health Corp	Retail	3.44%
13. Sangamo BioSciences Inc	Diversified Healthcare	2.83%
14. Fresenius Medical Care AG & Co KGaA	Healthcare Services	2.72%
15. Sanofi SA	Drugs	2.72%

MANAGEMENT TEAM

ALTRINSIC GLOBAL ADVISORS

Altrinsic Global Advisors follows a fundamental value approach to seek out high-quality undervalued companies worldwide. Altrinsic was founded by John Hock and associates and a sub-advisor to CI Investments Inc., a subsidiary of CI Financial Corp. CI Financial Corp. holds a minority interest in Altrinsic Global Advisors.

Andrew Waight

Over 35,000 financial advisors have chosen CI Investments as a partner. We believe that Canadians have the best opportunity for investments success by using the services of a professional financial advisor. Learn more at ci.com.

[1] Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. The indicated rates of return are the historical annual compounded total returns (net of fees and expenses payable by the fund) including changes in security value and reinvestment of all dividends/distributions and do not take into account sales, redemption, distribution or optional charges or income taxes payable by any securityholder that would have reduced returns. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.

[2] Portfolio allocations will fluctuate over the life of the mutual fund as the portfolio holdings and market value of each security changes. The portfolio manager(s) may change the portfolio allocations in some or all of the sectors.

[3] The risk level of a fund has been determined in accordance with a standardized risk classification methodology in National Instrument 81-102, that is based on the fund's historical volatility as measured by the 10-year standard deviation of the fund's returns. Where a fund has offered securities to the public for less than 10 years, the standardized methodology requires that the standard deviation of a reference mutual fund or index that reasonably approximates the fund's standard deviation be used to determine the fund's risk rating. Please note that historical performance may not be indicative of future returns and a fund's historical volatility may not be indicative of future volatility.

[4] Please refer to the fund's simplified prospectus for distribution information.

The contents are not to be used or construed as investment advice or as an endorsement or recommendation of any entity of security discussed.

®CI Investments and the CI Investments design are registered trademarks of CI Investments Inc. © CI Investments Inc. 2019. All rights reserved. 2019. "Trusted Partner in Wealth™" is a trademark of CI Investments Inc.

Published August 2019